Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1128 for AKI Prevention in Cardiac Surgery
NCT03941483Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP1128 in acute kidney injury (AKI) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Percentage of Participants Developing AKI Based on Serum Creatinine Criteria Within 72 Hrs From End of Surgery. Started Nov 2019; status: completed.
02
Drugs
ASP1128
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03941483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941483.